AZD2115 multiple ascending dose study
Study identifier:D3060C00002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Inhaled Doses of AZD2115 in Healthy Male Subjects
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD2115, Placebo
Sex
Male
Actual Enrollment
32
Study type
Interventional
Age
18 Years - 45 Years
Date
Study Start Date: 01 Oct 2011
Primary Completion Date: 01 Jul 2012
Study Completion Date: 01 Jul 2012
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Oct 2012 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 AZD2115 | Drug: AZD2115 Multiple dose, oral inhalation (nebuliser solution) |
| Placebo Comparator: 2 Placebo to AZD2115 | Drug: Placebo Multiple dose, oral inhalation (nebuliser solution) |
